Future designs could mimic dimeric or trimeric CD137L to enhance receptor engagement while incorporating tumor-microenvironment-sensitive linkers or controlled oligomerization strategies to improve specificity and minimize systemic toxicity. Here, TNFSF9 is linked to neoplasm.